
Rhythm Pharma shares rise after positive 6-month data on obesity drug setmelanotide in Prader-Willi syndrome patients.
Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 2...


